Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis

2021/11/22 by Rohit Loomba, Vlad Ratziu, Stephen A. Harrison +9 · 26 citations
Medicine · #Liver Disease Diagnosis and Treatment #Liver Diseases and Immunity #Diet, Metabolism, and Disease

paper · doi:10.1053/j.gastro.2021.10.051

Cited by

• A multisociety Delphi consensus statement on new fatty liver disease nomenclature
• Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. [europepmc]
• Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. [europepmc]
• The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications. [europepmc]
• Placebo Adverse Events in Non-alcoholic Steatohepatitis Clinical Trials: A Pooled Analysis of 2,944 Participants. [europepmc]
• Rejuvenation: Turning Back Time by Enhancing CISD2. [europepmc]
• Electro-acupuncture reduced steatosis on MRI-PDFF in patients with non-alcoholic steatohepatitis: a randomized controlled pilot clinical trial. [europepmc]
• Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. [europepmc]
• Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease. [europepmc]
• An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. [europepmc]
• Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study. [europepmc]
• Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. [europepmc]
• Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD. [europepmc]
• Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. [europepmc]
• Progression of non-alcoholic fatty liver disease and long-term outcomes: A nationwide paired liver biopsy cohort study. [europepmc]
• Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population. [europepmc]
• Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions. [europepmc]
• Exercise training improves serum biomarkers of liver fibroinflammation in patients with metabolic dysfunction-associated steatohepatitis. [europepmc]
• Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study. [europepmc]
• Therapeutic management of metabolic dysfunction associated steatotic liver disease. [europepmc]
• Endpoints in NASH Clinical Trials: Are We Blind in One Eye? [europepmc]
• MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH. [europepmc]
• Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease. [europepmc]
• Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology. [europepmc]
• New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease. [europepmc]
• AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases. [europepmc]